Displaying results 1 - 1 of 1
Clear search
STORM Therapeutics secures $56 million series C financing and doses first patient in phase 2 Sarcoma Trial of STC‑15
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation16 April 2026, Cambridge, UK: STORM Therapeutics Ltd.